A Clinico-Epidemiological study of Oral Lesions in Acquired Bullous Dermatoses by Jayasri, J
A CLINICO-EPIDEMIOLOGICAL STUDY OF
ORAL LESIONS IN ACQUIRED BULLOUS
DERMATOSES
Dissertation Submitted in
fulfilment of the university regulations for
MD DEGREE IN
DERMATOLOGY, VENEREOLOGY AND LEPROLOGY
(BRANCH XX)




            This is to certify that the dissertation entitled “A CLINICO-
EPIDEMIOLOGICAL STUDY OF ACQUIRED BULLOUS
DERMATOSES’’ is a bonafide work done by Dr. J. Jayasri, at Madras
Medical College, Chennai in partial fulfilment of the university rules and
regulations for award of M.D., Degree in Dermatology, Venereology and
Leprology (Branch-XX) under my guidance and supervision during the
academic year 2009 -2012.
Prof. S. JAYAKUMAR, M.D., D.D.,
Professor and Head of the Department,
Department of Dermatology,
Madras Medical College &
Rajiv Gandhi Govt. General Hospital,
Chennai – 3.
Prof. V. KANAGASABAI, M.D.,
The Dean
Madras Medical College &
Rajiv Gandhi Govt. General Hospital,
Chennai – 3.
DECLARATION
                I, DR. J. JAYASRI, solemnly declare that dissertation titled, “A
CLINICO-EPIDEMIOLOGICAL STUDY OF ORAL LESIONS IN
ACQUIRED BULLOUS DERMATOSES” is a bonafide work done by
me at Department of Dermatology and Leprosy, Madras Medical College,
Chennai-3 during the period of October 2009 to September 2011 under the
supervision of Prof. DR.S.JAYAKUMAR, M.D, D.D, Professor and
HOD, The Department of Dermatology and Leprosy, Madras Medical
College, Chennai. The dissertation is submitted to Tamilnadu Dr. M.G.R.
Medical University, towards partial fulfilment of requirement for the award
of M.D. Degree (Branch-XX) in DERMATOLOGY, VENEREOLOGY
AND LEPROLOGY.




        My sincere thanks to Prof. Dr. V. KANAGASABAI, M.D., Dean,
Madras Medical College for allowing me to do this dissertation and utilize
the institutional facilities.
ACKNOWLEDGEMENT
              I am gratefully indebted to Prof. Dr. S. JAYAKUMAR, M.D.,
D.D., Professor and Head, Department of Dermatology and Leprosy for his
invaluable guidance, motivation and help throughout the study. I would like
to express my sincere and heartful gratitude to Prof. Dr. V. SUDHA, M.D.,
D.V. D. D, Director, Institute of Venereology.
             I wish to thank Prof. Dr. D. PRABHAVATHY, M.D., D.D.,
Former Professor and Head, Department of Dermatology and Leprosy for
her constant support and motivation. I wish to thank Prof.
Dr. GAJENDRAN, M.D., D.V., Former Director, Institute of Venereology
for his constant support and motivation. I express my gratefulness to Prof.
Dr. V.SOMASUNDARAM, M.D., D.D., Former Professor and Head of
Department of Occupational Dermatology and Contact Dermatitis for his
constant motivation and guidance.
          I am very grateful to Prof. Dr. C. JANAKI M.D.,D.D., Department
of Dermatology (Mycology) for her invaluable guidance and help.
          I sincerely thank Prof. Dr. V. SAMPATH, M.D., Department of
Dermatology for his priceless support. I express my sincere gratitude to
Prof. Dr. R. ARUNADEVI, M.D., D.D., Professor of Leprosy for her
support. I thank Prof. Dr. S. NIRMALA, M.D., D.D., Department  of
Occupational and Contact Dermatitis for her benevolent help and support. I
thank Prof. Dr. R.PRIYAVATHANI, M.D., for her immense help.
          I specially thank Dr. R. MADHU, M.D., Assistant Professor,
Department of Dermatology (Mycology) for her immense guidance and
support. I incline to thank Dr. G. K. THARINI, M.D., and Dr. SAMUEL
JAYARAJ DANIEL, M.D (D.V.L)., Assistant Professors, Department of
Dermatology for their kind support and encouragement.
          I thank Dr. J. MANJULA, M.D., D.N.B., Dr. AFTHAB
JAMEELA WAHAB, M.D.,D.D., and Dr. S. SARAVANAN, M.D.,
Assistant Professors, Department of Occupational Dermatology and Contact
Dermatitis for their support and help.
         My sincere thanks to Dr. P. ELANGOVAN, M.D.,D.V. for his
valuable guidance. I thank Dr. K. VENKATESWARAN, M.D., D.V.,
Dr. S. THILAGAVATHY, M.D., D.V., Dr.P.MOHAN, M.D., D.V.,
Dr. S. ARUNKUMAR, M.D., D.V., Dr. S. KALAIVANI, M.D., D.V.,
Dr.  S. PRABAHAR, M.D(D.V.L)., Dr. V.N.S. AHAMED SHARIFF,
M.D (D.V.L)., Assistant Professors, Institute of Venereology for their help
and suggestions.
           I am thankful to the entire Department of Oral Pathology and
Department of Oral Maxillo-facial surgery, Tamilnadu Govt. Dental college,
for their kind support, help and guidance.
           I duly acknowledge the paramedical staff and my colleagues for their
help and favour. Last but not the least I am profoundly grateful to all
patients for their cooperation and participation in the study.
CONTENTS
S.No. Title Page No.
1. INTRODUTION 1
2. REVIEW OF LITERATURE 3
3. AIM OF THE STUDY 39
4. MATERIALS AND METHODS 40











Oral cavity occupies a unique position in the human body. As it is
situated anatomically between the skin externally and the intestinal
mucosa internally, it shows some properties of each in various aspects.
Hence it can act as a marker of both cutaneous as well as internal
diseases. A number of diseases affect both skin and the oral mucosa and
in some, the oral involvement precedes the skin disease and can well help
the disease to be identified earlier thereby making the management
feasible at an earlier course of the disease, thus reducing the morbidity of
the disease considerably.
             The oral mucosa differs from the skin anatomically in several
aspects. With the exception of the dorsum of the tongue and the hard
palate, stratum corneum and stratum granulosum are not present in the
mucous membrane of the mouth. Where these layers are absent, the
epithelial cells appear vacuolated as a result of their glycogen content.
The epithelial cells of the oral mucosa show only few well-developed
desmosomes and instead, they show numerous microvilli at their
borders.1
           A careful scrutiny of the oral mucosa becomes an essential and
integral part of dermatological examination, especially when it comes to
2vesiculobullous dermatoses. Autoimmune vesiculobullous disorders, in
particular, more frequently affect the oral cavity in a severe manner
affecting the oral intake and general nourishment of the body which in
turn increases the morbidity.
           The interpretation of signs and symptoms in oral cavity poses
difficulty due to its anatomical and functional properties. The vesicular
lesions easily rupture leaving erosions. Painful nature of most of the
vesiculobullous lesions leads to difficulty in maintaining proper oral
hygiene. The ulcers get easily infected and consequently become foul
smelling.
             Thus it is important to know the various oral manifestations of
vesiculobullous disorders in order to facilitate an early diagnosis and




               Blistering conditions of the oral mucosa can be due to trauma,
infection or immune-related diseases. The various vesiculo bullous
dermatoses involving both skin and oral cavity are classified as follows.2,3
1. Viral infections:
 A. Herpes simplex virus
       i)        Primary gingivostomatitis
       ii)       Recurrent herpes stomatitis
       iii)      Recurrent herpes labialis
  B. Varicella zoster virus
       i)        Primary varicella
       ii)       Herpes zoster
   C. Cox Sackie virus
       i)        Hand foot and mouth disease
       ii)       Herpangina
2. Autoimmune blistering disorders:









ii) Epidermolysis bullosa acquisita
iii) Mucous membrane pemphigoid
iv) Dermatitis herpetiformis
v) Linear IgA disease
vi) Bullous lupus erythematosus
vii) Bullous lichen planus
3. Drug eruptions:
i) Erythema multiforme (can be drug & virus induced)
ii) Stevens Johnson syndrome
iii) Toxic epidermal necrolysis
iv) Bullous fixed drug eruption.
VIRAL INFECTIONS
Herpes simplex:
A variety of infections of the oral cavity are caused by herpes
simplex  viruses,  commonly  type  I  and  rarely  type  II.4,5 These infections
5may be primary or inoculation infections or secondary or recurrent
infections. Chronic infection of oral and perioral tissues can occur in
immunocompromised individuals.6
Clinical features: Herpes simplex labialis, also known as cold
sores or fever blisters, is the most common presentation characterised by
recurrent episodic lesions that arise at the muco-cutaneous junction as
grouped papules on an erythematous base which progress to vesicles,
pustules, erosions and scab. The lesions heal over 7-10 days without
scarring.7
Primary herpetic gingivostomatitis is a self limited acute infection,
occurring most frequently in the first two years of life but can occur at
any age in those with no prior exposure to the virus.7,8  Patients are ill
with fever, malaise, pain & excessive salivation. The oral lesions
characteristically affect the interdental papillae first, causing erythema,
edema and hemorrhage. Lesions rapidly progress to involve the other
areas in the mouth and lips causing a diffuse painful stomatitis. The
regional lymph glands are enlarged and tender. The fever subsides after
3-5 days and recovery is complete in 2 weeks.9
Recurrent intraoral herpes simplex virus infections are rare. In this,
the lesions are grouped and affect the well keratinised mucosa overlying
6the hard palate or alveolar ridges & areas of trauma. They occur in an
episodic fashion similar to recurrent herpes simplex labialis.10
Chronic indolent lesions, usually ulcerative or nodular, may be
seen in neutropenic, immunosuppressed and chronic leukemia patients.11
Histopathology: Earliest specific finding is the nuclear changes in
the epidermal cells, including peripheral clumping of chromatin,
homogenous ‘ground glass’ appearance and ballooning of nuclei.
Combined mononuclear and polymorphonuclear infiltrate is seen.
Vacuolization is the earliest cytoplasmic alteration. Late lesions show the
eosinophilic intranuclear inclusion bodies and a dermal infiltrate of
numerous neutrophils. Vesicles appear secondary to cell degeneration
(secondary acantholysis).1,2
Chicken pox:
Primary varicella or chickenpox, caused by Varicella zoster virus,
usually occurs in children aged 3-6 years, who are not immunized at the
time of their first exposure to the virus. Prodromal symptoms like fever
and myalgia occur. Itchy papules appear in crops over the trunk and then
spread to the head and extremities. They transform into stages of vesicle,
pustule, erosion and scab. This is followed by antibody production and
convalescence. The virus usually becomes latent in the dorsal root
7ganglia. In the oral cavity, it may present with a few vesiculopustules on
the oral mucosa, particularly on the soft palate, uvula or the anterior
tonsillar pillar but without gingival involvement.12
Herpes zoster:
Herpes zoster affecting the maxillary or mandibular divisions of
the trigeminal nerve, glossopharyngeal nerve or the geniculate ganglion
may cause oral lesions. Oral ulcers appear in the distribution of the
involved branch of the nerve.13
When the mandibular branch is involved, lesions are seen over
ipsilateral half of the tongue, floor of the mouth, lower labial and buccal
mucosa whereas palate, upper gingivae and the buccal sulcus are
involved in maxillary branch zoster.14
Ramsay-Hunt Syndrome, characterised by unilateral facial palsy
with vesicles and ulcers in the ipsilateral ear, soft palate and anterior 2/3rd
of the tongue results due to involvement of the geniculate ganglion of
facial nerve.14
Glossopharyngeal zoster produces pain in the ear and pharynx,
with vesicles and ulcers on the soft palate and the ear.12
8Microscopy: Histopathological features are similar to herpes
simplex except for the more pronounced vascular changes.1,2
Hand, foot and mouth disease:
Hand, foot and mouth disease is a relatively rare, benign self
limiting, highly contagious viral infection, mainly affecting infants and
children. No racial or gender predilection has been recognised. The first
Indian epidemic was recorded in Kerala in 2003.15
Aetiopathogenesis: Coxsackie viruses, enteroviruses and the
echoviruses are the causative agents of which Coxsackie A16 and
Enterovirus 71 are the most commonly implicated agents. Transmission
occurs by aerosolised droplets, fecal, feco-oral and oral-oral routes.16
Clinical features: One  or  two  days  after  the  onset  of  prodromal
symptoms, painful sores or papulovesicules with perilesional erythema,
develop in the oral cavity usually on the tongue, palate, gums and buccal
mucosa. Skin rash develops over 1-2 days15 consisting of flat or raised red
spots, sometimes with blisters surrounded by erythematous halo on the
palms, soles, buttocks and rarely over knees and genitals. Lesions in the
palms  and  soles  are  elliptical  with  their  long  axis  parallel  to  the  skin
lines.15 By the 7th day, the titre of neutralising antibodies increase and the
virus is eliminated.16
9Herpangina:
Herpangina is an acute febrile illness caused by Coxsackie virus.
Coxsackie virus A16, Coxsackie virus B and Enterovirus 71 have been
implicated most often. Less common causes include echovirus,
parechovirus 1, adenovirus, and Herpes simplex virus (HSV).17,18
Clinical features: Herpangina typically occurs during the summer
and usually develops in children aged 3-10 years, occasionally occurring
in newborns, adolescents and young adults without any sexual
predilection. It is characterised by malaise, anorexia, irritability, low
grade fever, slightly enlarged & tender anterior cervical
lymphadenopathy and papulovesicular grouped eruptions or ulcerative
lesions in the oropharyngeal mucosa, especially on the soft palate and
uvula (enanthem). Occasionally lesions may occur on the tongue and
posterior buccal mucosa. The ulcers may persist for up to one week, even
after the fever has subsided. 19
It can occur in association with enteroviral exanthem, aseptic
meningitis, encephalitis, acute flaccid paralysis and other clinical
syndromes. Diagnosis is clinical. Laboratory studies are generally not
indicated as it is a mild and self-limiting illness. No histopathologic
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findings are specific to herpangina. Isolation of the virus by culture can
confirm  the diagnosis.20
Differential diagnoses include aphthous stomatitis, acute retroviral
syndrome, Hand-Foot and Mouth Disease, Herpes Simplex, Infectious
Mononucleosis, bacterial and viral pharyngitis. 20
AUTOIMMUNE BLISTERING DISORDERS:
Pemphigus is a group of potentially life threatening autoimmune
diseases characterized by cutaneous and/or mucosal blistering.21
Pemphigus can be classified into six types: pemphigus vulgaris,
pemphigus vegetans, pemphigus erythematosus, pemphigus foliaceus,
paraneoplastic pemphigus and IgA pemphigus.22
Pemphigus vulgaris:
It is the most common variant that presents with oral lesions as an
initial manifestation in 50% of cases.23 It affects only 1-5 patients per
million population per year.24 The peak incidence of pemphigus vulgaris
occurs between the fourth and sixth decades of life with a male to female
ratio of 1:2.25
Pathogenesis:  The precise pathogenesis of pemphigus vulgaris is
not clear. Autoantibodies directed against desmoglein 1 & 3 are the main
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underlying factors in the pathogenesis which interfere with the cell-cell
adhesion function of the desmosomes leading to loss of cell-cell cohesion
(acantholysis) either directly by steric hindrance or it may be mediated by
signal transduction. Proteinases, likely induced by pemphigus antigen-
antibody complex, are thought to play an important role in acantholysis.1
Recent studies have shown that acantholysis can occur in the presence of
auto antibodies against 9 alpha nicotinic acetylcholine receptor.26
Clinical features: Flaccid blisters filled with clear fluid arise either
on normal skin or an erythematous base over the scalp, face, axillae,
groins and pressure points. These rupture and produce painful erosions
that extend at the edges in an irregular manner. Gentle lateral pressure on
unaffected skin or margin of the lesion causes the epithelium to
disintegrate  and  form a  bulla  or  an  erosion  (Nikolsky's  sign).  Nearly  all
patients have mucosal lesions, and at the time of presentation oral lesions
are seen in 50 to 70% of patients.  These may precede cutaneous lesions
by months or be the only manifestation of the disease.27-29
The oral lesions are characterized by blisters that rapidly rupture,
resulting in painful erosions.30 While  any  area  in  the  oral  cavity  can  be
involved, the soft palate, buccal mucosa and lips are predominantly
affected.30 The buccal mucosa is the most common site, followed by
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palate, lips, tongue and gingiva.23,30 Nikolsky's sign is useful in
demonstrating the reduced epithelial adhesion when no lesions are
present on examination and to differentiate from other erosive lesions.2
Other mucosal surfaces may be involved, including the
conjunctiva, nasal, pharynx, larynx, oesophagus, urethra, vulva and
cervix.27
A Tzanck smear taken from the floor of a fresh bulla or an early
erosion shows acantholytic keratinocytes, arranged singularly or in
clusters, with rounded, condensed cytoplasm and an enlarged nucleus
with peripherally palisaded chromatin and enlarged nucleoli.31
Histopathology: Suprabasal bulla with acantholytic cells in the
bulla cavity is the typical picture. The basal keratinocytes are separated
from one another due to the loss of attachment, but remain firmly
attached to the basement membrane like a row of tombstone.1
Eosinophilic spongiosis may be seen in early cases. Older lesions will
show intraepidermal bulla due to epithelial regeneration.32
Direct immunofluorescence study: Immunoglobulins especially
IgG and complement are deposited in the intercellular space giving the
characteristic “fish net” appearance.5,27 It  is  usually  positive  in  100% of
cases when the disease is active.33,34 Spongiotic dermatitis, psoriasis,
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bullous impetigo, and epidermis adjacent to ulcers secondary to a number
of disorders may have squamous intercellular substance IgG due to
insulation of serum into the intercellular substance.1
Other investigations: Indirect immunofluorescence studies enable
a search for circulating auto antibodies in the patient’s serum and are
usually performed after direct immunofluorescence studies reveal the
presence of antibody deposits in the mucosa. Specific enzyme linked
immunosorbent assays (ELISA) and immunoblotting are also available
for detecting desmoglein 3 and desmoglein 1 auto antibodies.34,35
Pemphigus vegetans:
Pemphigus vegetans is a rare variant of pemphigus vulgaris which
is characterized by vegetating erosions, primarily in flexures. Two
subtypes are recognized; the severe Neumann type and the mild
Hallopeau type.36
Pathogenesis: Antibodies react with the 130 kDa desmoglein 1
antigen and possibly other antigens in both types.36-40 Antibodies in the
Hallopeau type also react with desmocollins 1 and 2.41 Complement
fixation might be responsible for the marked cutaneous infiltration of
neutrophils and eosinophils.38
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Clinical features: In  the  Neumann  type, vesicles and bullae
rupture to form hypertrophic granulating erosions, which bleed easily.
The lesions evolve into vegetating masses exuding serum and pus.
Erosions at the edge of the lesions induce new vegetations. In the
Hallopeau type, early lesions are characterised by pustules rather than
vesicles which soon progress to vegetating plaques. Spontaneous
remission is possible.42
Oral lesions are less frequent than in pemphigus vulgaris.43 Usual
presentation is marked by serpiginous ulcers mainly on the dorsum of the
tongue and lips. Papillomatous proliferations may be seen on the angle of
the lips. Hyperplastic masses on the tongue can give a cerebriform
appearance.5,44
Microscopy: In the Neumann type, early changes are similar to
pemphigus vulgaris. In the late stages, verrucous hyperplasia and villi
formation will occur and the acantholytic cells are inconspicuous.
Suprabasal clefts filled with numerous eosinophils and degenerated
acantholytic epidermal cells are seen in Hallopeau type, which becomes
identical to the Neumann type in late stages. Eosinophilic pustules and
microabscesses are seen.1,43
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Direct immunofluorescence study: This demonstrates
intercellular IgG sometimes with C3. Circulating intercellular antibodies
can be detected in most patients by indirect immunofluorescence.45
Pemphius foliaceous:
Pemphigus foliaceus is less common worldwide than pemphigus
vulgaris and in most parts of the world, probably accounts for only 10–
20% of cases of pemphigus.46-48 It occurs in both sporadic and endemic
forms (Brazil).47
Pathogenesis: Autoantibodies directed against desmoglein-1, a
160-kDa desmosomal cadherin and certain drugs containing thiol groups
like captopril, penicillamine etc. have been implicated to interfere with
the function of desmosomes in the upper epidermis where desmoglein 3,
which compensates for the loss of desmoglein 1 in the lower epidermis, is
relatively sparse. This results in subcorneal separation. These antibodies
stimulate epidermal cells to secrete plasminogen activator which results
in increased plasminogen resulting in acantholysis.49
Clinical features: Lesions are seen mainly involving the
‘seborrhoeic’ areas like scalp, face, chest and upper back. Scaly lesions
predominate as blisters are transient and rarely seen due to the very
superficial level of the cleavage, leading to rapid rupture of the vesicles.
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The scales separate leaving well-demarcated, crusted erosions surrounded
by erythema.45
Oral  lesions  are  uncommon  as  the  desmoglein  3,  which  is
distributed throughout the entire epithelium compensates for the loss of
desmoglein 1. In the skin, desmoglein 3 is deficient at the subcorneal
level where the loss of desmoglein 1 leads to subcorneal blister
formation. Rarely superficial erosions can occur.5
Microscopy: Subcorneal bulla containing fibrin, some neutrophils
and scattered acantholytic keratinocytes is seen. Epidermal eosinophilic
spongiosis or neutrophilic spongiosis may precede the blisters. 50, 51
Pemphigus erythematosus:
Pemphigus erythematosus is a variant of pemphigus foliaceus with
immunological features of both lupus erythematosus and pemphigus.52,53
Clinical features: Erythematous, scaly lesions are seen over the
nose and cheeks in a butterfly distribution simulating cutaneous lupus
erythematosus or seborrhoeic dermatitis. Sunlight may exacerbate the
disease. Oral mucosa is involved rarely. Superficial erosions may occur.
This condition usually evolves into classical pemphigus foliaceus,
sometimes to pemphigus vulgaris.54
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Microscopy: Histology is not specific. Features are similar to
pemphigus foliaceus.54 Rarely interface dermatitis may also be present,
making distinction from lupus erythematosus difficult.1
Direct immunofluorescence: Both  granular  IgG  and  C3  at  the
basement membrane zone and intercellular IgG and C3 in the epidermis
are seen.5,54
IgA pemphigus:
This rare entity comprises a heterogeneous group clinically,
histologically and immunologically. Two main subtypes are the
subcorneal pustular type and the intraepidermal neutrophilic type.5
Pathogenesis: Auto-antibodies are directed against desmocollin-1,
which is a desmosomal component located mainly in the upper epidermis,
in case of subcorneal pustular type 55-56 and occasionally in the
intraepidermal neutrophilic type.55 In the intraepidermal neutrophilic
type, antigens resembling desmogleins-1 or 3 have been implicated as the
target antigens. 56,57 The pathogenic antibodies are of IgA variety which
get deposited in the intercellular spaces of the epidermis.58
Clinical features: The disease mainly affects adults, though
childhood cases have been reported.59 Patients with both types have
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flaccid vesicles or pustules arising on either erythematous or normal skin.
The lesions may be pruritic and show a circinate or annular configuration
with central clearance and evolve to crusted or scaly erythematous
macules. The sites of predilection are the axillae and groins. Nikolsky’s
sign is usually negative. In some cases, the flaccid pustules resemble
those seen in subcorneal pustular dermatosis. Mucous membrane
involvement is very rare. Erosions or blisters can occur rarely. 60
Microscopy: A neutrophil-rich polymorphonuclear infiltrate in the
epidermis is seen. Subcorneal pustules are seen in the subcorneal pustular
dermatosis type whereas intraepidermal pustules are seen in the
intraepidermal neutrophilic type.1 Acantholysis is usually sparse or
absent.53
Direct immunoflourescence study: The hallmark of these
disorders is intercellular IgA deposition at the upper level of  epidermis in
subcorneal type, at the lower or entire epidermis in intraepidermal type.61
Circulating IgA is either undetectable or present in low titres.60
Paraneoplastic pemphigus:
Paraneoplastic pemphigus (PNP) was originally described by
Anhalt et al. in 1990, a mucocutaneous disease associated with neoplasia,
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most commonly B-cell lymphoproliferative disorders, thymoma,
sarcomas and carcinomas.62
Pathogenesis: It is believed that the tumour antigens evoke a
humoral autoimmune response. This immune reaction being directed
against the neoplasm, provides protection against progression or
dissemination of the tumour, but also cross-reacts with the host epithelial
tissues, thus producing the mucocutaneous lesions. 62
Clinical features: PNP consists of a polymorphous
mucocutaneous eruption that overlaps with erythema multiforme and
lichen planus pemphigoides including blisters, erosions, particularly on
the upper body, and palmoplantar target lesion.5 Involvement of the oral
mucosa is the rule with the exception of thymoma associated
paraneoplastic pemphigus. The mean age of onset is 60 years.5
Paraneoplastic pemphigus has a poor prognosis with a mortality rate of
around 90%. Successful treatment of the underlying malignancy results in
remission of the associated pemphigus lesions.63
Microscopy: Histology depends upon the morphology of the
lesion that is biopsied. Necrosis of keratinocytes or vacuolar interface
dermatitis or suprabasal clefting with acantholysis  is seen.1, 64
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Direct immunoflourescence study: IgG deposits in the epithelial
intercellular spaces and granular deposition of complement along the
basement membrane zone is seen.1,65
Indirect immunofluorescence is positive in both non-stratifying
(simple and transitional) and stratifying epithelia. Antibodies are
predominantly antiplakin antibodies of the IgG1 subclass. 65
Bullous pemphigoid:
Bullous pemphigoid is the most common type among the
subepidermal bullous disorders.
Pathogenesis: IgG autoantibodies directed against  two antigens:
BPAg1 (BP230), an intracellular component of the hemidesmosome;
BPAg2 (BP180,  type  XVII  collagen)  a  transmembranous  protein  with  a
collagenous extracellular domain, bind to the basement membrane in
patients with bullous pemphigoid. The binding of these antibodies at the
basement membrane activates complement (C3) and inflammatory
mediators which lead to subepidermal cleavage.66,67
Clinical features: Bullous pemphigoid mainly affects elderly
people, with onset usually after 60 years of age.68 Women are affected
more (M:F – 1 to 1.7).69  It commonly starts with itching and a non-
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specific rash on the limbs that may be either urticaria-like or eczematous.
The pruritus may persist for many months. The urticarial prodrome
usually lasts 1–3 weeks before blisters occur while eczematous prodrome
may precede the blisters by several months. Blisters are tense, dome
shaped and appear mainly on the flexural aspects of limbs and on the
central abdomen.5,70
Oral manifestations occur in 40% of cases and follow cutaneous
eruptions. Generally bullous pemphigoid is characterised by smaller, slow
growing and less painful oral lesions.66,67 Because of the thick nature of
the blister roof, intact vesicles and bullae can be seen in the oral cavity
affecting the buccal mucosa, palate, gingival, tongue and lower lip.
Gingiva can be affected in 16% resulting in desquamative gingivitis.69
Microscopy: Histopathology shows subepidermal bulla with the
bulla cavity containing fibrin and eosinophils along with a dermal
neutrophilic and eosinophilic infiltrate.71
Direct immunofluorescence study: Direct immunofluorescence
study will show linear C3 deposition with or without IgG along the
basement membrane zone. Use of salt split skin will reveal the deposits in
the epidermal side or roof of the blister.5,71
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Vegetating cicatricial pemphigoid (pemphigoid vegetans):
A rare subset of bullous pemphigoid that is clinically
indistinguishable from pemphigus vegetans as it produces vegetating
lesions and sometimes oral blisters and erosions. Direct
immunofluorescence in this condition shows linear deposits of IgG and
C3  at  the  epithelial  basement  membrane  zone  on  oral  biopsy,  but  there
are no circulating anti-basement membrane antibodies.72,73 Palate and
gingiva are mainly involved.74
Epidermolysis Bullosa Acquisita:
EBA is a chronic blistering disease that can affect the skin and the
oral mucosa. The circulating autoantibodies against collagen VII react to
a dermal protein, which is a constituent of anchoring fibrils. The
anchoring fibrils anchor the epidermis and its underlying basement
membrane zone to the papillary dermis, whose function is lost due to
these antibodies.75
Clinical features: There is no race or sex predilection. It occurs
primarily in adults, although it also has been described in children and
may occur in any age group.76
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The classic form of EBA is characterized by fragility of the skin,
blisters that coalesce and break open, and vesicles or bullae with localized
skin erosions. Lesions heal with milia and scarring. The exposed skin
areas such as knees, elbows, nails, feet, and hands are most often the
target areas for injury. Loss of hair, nails, and esophageal involvement
has been described.77
Microscopy: The histological findings depend upon the stage of
the disease. The blister is seen at the subepidermal level. In the
inflammatory type of the disease, there is a heavy predominantly
neutrophilic infiltrate in the dermis whereas in the mechanobullous non-
inflammatory phase, the infiltrate is usually sparse or absent.78
Direct immunofluorescence: Linear IgG deposits at the basement-
membrane zone is found in all patients. Linear IgA and IgM may also be
seen.79 C3 has been reported in most cases. The basement membrane
staining may be broader than that seen in bullous pemphigoid. A
diagnostic U-serrated pattern has been described.79 In salt split skin,
deposits are seen on the dermal side.80
Immune electron microscopy shows IgG and C3 in the sublamina
densa zone of the epithelial basement membrane.81
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Mucous membrane pemphigoid (MMP):
MMP is an autoimmune vesiculobullous disease of the mucosal
tissues and, rarely, the skin. It usually affects adults over 40 years of age
and occasionally children. Only 10 cases of childhood MMP affecting the
oral mucosa have been reported in the literature.82 MMP occurs twice as
often in women as in men, and no racial predilection exists.
Two types of skin lesion may occur, the most common of which is
a generalized bullous eruption mimicking bullous pemphigoid. The
second type is a localized one with erythematous plaques situated mainly
over the extremities over which recurrent blistering occurs, with
subsequent scarring and hyperpigmentation.83
Oral mucosal surfaces are the most frequently affected sites,
predominantly the gingiva, where it presents as desquamative gingivitis.
MMP may result in scar formation in other mucosal sites such as the
conjunctiva but oral scarring is rare.84
It is a benign disease but can become life-threatening if laryngeal
or oro-esophageal involvement occurs leading to stenosis. Progressive
ocular lesions may result in entropion and blindness.85,86
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Microscopy : Subepidermal bulla with an intact basal layer on the
roof with minimal inflammatory infiltrate is seen in the dermis.87
Lamellar fibrosis is present beneath the epidermis. In the mucosal
surfaces, a lichenoid infiltrate is seen. 1
Direct immunofluorescence study: This shows linear deposition
of IgG, C3 and rarely IgA along the basement membrane.88
Dermatitis herpetiformis:
Dermatitis herpetiformis (DH) is a rare, intensely pruritic, chronic,
recurrent, papulovesicular disease.
Pathogenesis: There  is  a  strong  association  with  HLA  DR3  and
HLA DQw2.89 There is an underlying gluten-sensitive enteropathy in all
patients that may be asymptomatic. The exact mechanism by which
gluten causes blisters in the skin is still unknown. Autoantibodies (IgA)
and T-cell reactions to tissue transglutaminases, are related to the
pathogenesis.90 The tissue transglutaminases cleave the gliadin into
antigenic peptides and this may contribute to their role in pathogenesis.91
The IgA deposits have been shown to be chemoattractant to neutrophils
and there is activation of complement pathway which leads to the tissue
injury. 92
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Clinical features: It affects men slightly more frequently than
women. In a majority of cases the onset is between the second and fourth
decades of life.93 However, it can appear in later years and even in
childhood. A positive family history is seen in 10.5% of patients.94
The onset may be acute or gradual, and pruritus is usually the first
and predominant symptom. Early lesions are erythematous papules,
urticarial weals or groups of small vesicles which often excoriate rapidly.
The vesicles are usually seen in groups situated over erythematous
plaques. Rarely blisters of about 1–2 cm diameter can occur. The
distribution of the lesions is characteristic, with involvement of extensor
aspects of the limbs, especially the knees, elbows, buttocks and the natal
cleft.68
Incidence of oral lesions varies in various studies94 and is generally
rare. Recurrent aphthous ulceration is the most common lesion of the oral
mucosa in those patients with symptomatic gut disease, followed by
cheilitis,  glossitis  and  angular  stomatitis  that  occur  due  to
malnourishment. Various studies have reported papulovesicular lesions,
ulcers and erosions which may be associated with pain or burning
sensation. Enamel defects occur in DH patients similar to celiac disease.95
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Microscopy: The lesional skin will show polymorphonuclear
leucocyte microabscesses in the tips of the papillary dermis that are
multiloculated. Initially neutrophils predominate, but as they enlarge,
eosinophils become more conspicuous. Later, the microabscesses fuse to
form unilocular abscess, subepithelial blisters and then, erosions.1
Direct immunofluorescence study: Granular deposits of IgA
along the basement membrane zone is seen in both lesional and non-
lesional skin.1
Linear immunoglobulin A (IgA) Disease:
Linear IgA dermatosis (LAD) is an autoimmune subepidermal
vesiculobullous disease that may be idiopathic or drug-induced. It can
affect all ages from infants of few months age to the elderly (mean age of
onset < 5 years and >60 years respectively), with no sex predilection. The
childhood variety is said to be common in South Asian countries and has
been historically referred to as chronic bullous dermatosis of
childhood.96,97
Pathophysiology:  IgA antibodies directed at a number of different
target antigens, seem to be the underlying pathogenesis. The major
antigen is BP180/collagen XVII and its shed ectodomain, LAD1 with
molecular weights of 97 and 120 kDa. Other antigens include BP230,
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LAD285, rarely collagen VII, the anchoring fibril component. In cases
where type VII collagen is the target antigen against which the antibody
response is directed, patients are less likely to be responsive to
treatment.98
Clinical features: In children, the lesions comprise urticated
plaques and papules, and annular, polycyclic lesions often with blistering
around the edge, called as “the string of pearls” sign.  Remission has been
reported to occur in 64% of children, in most cases within 2 years.
Disease of adults is more protracted with a mean duration of 5.6 years,
lasting anywhere from 1-15 years. The blisters may arise from normal
skin or from urticated plaques and can be haemorrhagic. The
characteristic annular lesions with blisters around the edges are less
common. The remission rate in adults is less than that in children
(48%).99
Approximately in 80% of patients mucosal lesions can be observed
(oral, ocular, nasal or genital mucosa). Almost 60 – 70 % of LAD patients
have oral mucosal lesions. The most frequent oral lesions are painful
erosive or ulcerative lesions caused by the rupture of bullae. These
ulcerative or erosive lesions may appear anywhere in the oral mucosa,
including vestibular mucosa and the tongue. 99
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Microscopy: The histological features are not specific for the
condition. The subepidermal vesicles may contain numerous eosinophils
suggestive of pemphigoid. In some blisters, neutrophils predominate and
dermal capillary microabscesses are seen, suggesting dermatitis
herpetiformis. Others show subepidermal blisters with non-specific
features.71
Direct Immunofluorescence study: Linear deposition of IgA
along the basement membrane zone is seen. There may also be other
immunoreactants, IgG, IgM or C3. In salt split skin, the deposition of the
autoantibodies is in the epidermal or dermal aspect or both.100
Bullous lichen planus:
Lichen planus is a common disease with worldwide distribution.
The incidence of oral lichen planus varies from  0.5-2%.101 About 30-
70% of patients with skin lesions have oral involvement, while 15%
present with only oral involvement.102 Exact aetiology is unknown and it
is a disease of multifactorial origin which includes genetic predisposition,
viral infection, various drugs, dental amalgam filling, etc. 102
A familial form, inherited as an autosomal dominant trait affects
extremities in childhood and adolescent age group. Lichen planus
pemphigoides is a condition where Lichen planus, a T-cell mediated
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condition and Bullous pemphigoid, a humoral mediated disease coexist,
affecting the skin and the oral mucosa. 103
Distinct clinical subtypes such as reticular, plaque, erosive,
atrophic and bullous types are recognised. Of these, the reticular type is
the commonest while bullous variety is the rarest with only few cases
reported till date.2
Bullae are often seen in the buccal mucosa and appear as flattened
gelatinous plaques surrounded by a zone of erythema. Whitish reticulate
lesions and striae can be found adjacent to the bullae or other intra oral
locations. Symptoms include mild pain or burning discomfort.2
Histopathology: A subepidermal bulla with lichenoid infiltrate is
seen.5 In the oral  mucosa,  a  subepithelial  separation with the roof of  the
bulla composed of disoriented fragmented basal cells. The floor shows
few fragmented basal cells overlying fibrous tissue with a zonal
lymphocyte infiltrate. The margins blend with the adjacent mucosa that
shows the typical changes of classical lichen planus as basal cell
degeneration.2
Direct Immunofluorescence study: Deposition of fibrinogen in a
fringe pattern along the basement membrane is the consistent finding.2
Occasionally, IgM, IgG and C3 may be seen.1
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Bullous lupus erythematosus:
Blistering eruptions are rare cutaneous manifestations of lupus
erythematosus (LE) that may be caused by different mechanisms.
Subepidermal clefting with frank vesiculation may occur in early lesions
of acute, subacute and chronic cutaneous LE due to a severe vacuolar
degeneration of the dermoepidermal junction. These vesiculobullous
lesions are considered to be LE-specific.104
Pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita,
dermatitis herpetiformis, and linear IgA bullous dermatosis have all been
reported in association with LE. These blistering eruptions are considered
to be non-specific for LE.105
Bullous SLE is a separate subset, with distinct clinical and
histopathological features. The target antigen for the IgG and IgA auto-
antibodies is type VII collagen, but other unknown antigens may also be
involved in bulla formation.105  Rarely drugs like hydralazine and IFN ?
may precipitate bullous SLE.106,107
Clinical features: The bullous lesions are predominantly seen on
the face, neck and upper trunk, but may be more widespread, and may
heal with milia formation. In Subacute cutaneous LE, erythema-
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multiforme (EM)-like lesions can occur, a condition described as
Rowell's syndrome. One third of the patients present with oral lesions.108
Microscopy: Histologically, the bullae are subepidermal with a
neutrophilic infiltrate, occasionally resulting in microabscesses
resembling dermatitis herpetiformis.109
Direct Immunofluorescence study: DIF studies show a linear
deposition of IgA, IgG and IgM and to a lesser extent, C3 at the basement
membrane, resembling bullous pemphigoid.110
Other findings: Electron microscopy shows the immunoreactants
to be in the sublamina densa in contrast to pemphigoid, where it is seen in
the lamina lucida. 110
Erythema Multiforme (EM):
Erythema Multiforme is a hypersensitivity reaction usually
triggered   by  infections, most commonly herpes simplex virus. Many
different virus  infections  have  been  reported  to  trigger  EM  including
Mycoplasma pneumonia, Parapoxvirus, Varicella zoster virus,
Adenovirus, Hepatitis viruses, Human  immunodeficiency  virus  (HIV),
Cytomegalovirus  and  various   viral  vaccines. Many drugs have been
reported to trigger EM including barbiturates, sulphonamides,
33
phenothiazines, penicillins, anticonvulsants and non steroidal anti
inflammatory drugs.111,112
Clinical features: In erythema multiforme minor, mucous
membrane involvement is mild or even absent. Erythema over the lips
and buccal mucosa is the commonest manifestation. Sometimes blisters
develop and quickly break to form erosions and ulcers. In  EM major, one
or  more mucous membranes are typically affected. Most often the oral
mucosa is involved (95-100%), most commonly lips, buccal mucosa and
tongue, less commonly floor of the mouth, palate and gums.113
Lesions may remain stationary or slowly enlarge over several
weeks or months (persistent erythema multiforme).114,115
Mucosal lesions range from tender superficial erythematous and
hyperkeratotic plaques to painful deep hemorrhagic bullae and erosions.
The blisters break quickly to leave large, shallow, irregular shaped,
painful ulcers that are covered by a whitish pseudomembrane. Typically
the lips are swollen with haemorrhagic crusts. The patient may have
difficulty in speaking or swallowing due to pain. Oral EM is a distinct
variety that manifests as chronic and recurrent lesions in the oral cavity
alone. The diagnosis of this condition is by exclusion.116
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Other mucosal sites that may get affected include eye, anus,
genitals, respiratory tract and gastrointestinal tract. With mycoplasma
pneumonia, the mucous membranes may be the only affected sites.117
Diagnosis: An etiology of herpes simplex virus can be established
by evaluating the following criteria: recurrent EM, history of recurrent
herpes, recent clinical herpes (preceding EM by 3 weeks) and
demonstration of a recent HSV infection (seroconversion). Drug
involvement is possible when there is a chronological relationship
between the drug use and the eruption.118,119
Microscopy: The histology of EM is characteristic but not
diagnostic.  It  varies  with  the  age  of  the  lesion  and  its  clinical
appearance.120 Vacuolization of the basal cell layer, infiltrate of
lymphocytes along the dermo-epidermal junction and a sparse,
superficial, perivascular lymphoid infiltrate are seen in early stages1. The
bullous lesions and desquamating lesions show subepithelial separation
with numerous necrotic keratinocytes surrounded by lymphocytes
(satellite cell necrosis). Immunostaining is not specific.120
In the drug induced variety, keratinocyte necrosis, microscopic
blister formation, and pigmentary incontinenc are more. In those
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associated with herpes simplex virus infection, there is more exocytosis,
liquefaction degeneration of the basal layer and papillary dermal edema.1
Stevens-Johnson syndrome (SJS):
Stevens-Johnson syndrome and Toxic epidermal necrolysis appear
to be the the same disease that vary in the severity based on body surface
area involvement (<10- SJS; 10-30%- SJS TEN overlap; >30%- TEN).
Various drugs have been implicated in their pathogenesis, mainly
sulphonamides, beta lactam antibiotics, analgesics and non steroidal anti
inflammatory agents(NSAIDs).121
The skin eruptions are preceded by a prodrome of high fever,
malaise, arthralgia and myalgia lasting for 1-13 days.  Extensive target
lesions, blisters and erosions occur.  Oral mucosa is involved in 100% of
the cases,122 showing extensive bulla formation, erosions and a greyish
white membrane leading to the characteristic hemorrhagic crusting of the
lips and the mouth. Other mucosa like eyes, genital and anal mucosa are
also involved. Mortality rate ranges from 5-15% due to infection,
toxaemia and renal damage. 123
Microscopy: Histopathology is similar to erythema multiforme
with necrosis of keratinocytes and dermal infiltrate.123 Necrotic
keratinocytes are more numerous involving full thickness of the
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epidermis and subepidermal bulla is seen. The infiltrate is sparse in toxic
epidermal necrolysis compared to erythema multiforme.1
Toxic epidermal necrolysis:
Toxic epidermal necrolysis is a rare clinicopathological entity with
a high mortality rate (30-40%).  An increased incidence of the disease in
patients with HIV/Acquired immunodeficiency syndrome (AIDS) has
been recorded.124
A prodromal illness precedes mucocutaneous manifestations by 1-2
days (1 day – 3 weeks). Entire skin surface and oral mucosa may be
involved. Early skin lesions include macules with purpuric and blistering
centre, urticarial or erythema multiforme which rapidly progresses to
confluent erythema, followed by blistering and sloughing of large areas
of skin in sheets. Nikolsky’s sign may be positive.125
Oral lesions are seen in 95% of patients. They may precede the
skin  lesions  by  a  day  or  so  and  may  persist.126 Gingival lesions are
common and clinically are inflamed, with blister formation leading to
painful, widespread erosions. Conjunctiva, cornea, iris and genital
mucosa are severely affected.127
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Microscopy: Early changes include epidermal spongiosis,
exocytosis and moderate perivascular infiltrate. Later, necrosis of the
whole epithelium which gets detached from the underlying lamina
propria is seen.127
Other findings include anemia, leucopenia, thrombocytopenia,
increase in aminotransferase levels, interstitial edema in chest X-rays are
seen.128
Fixed drug eruption:
Fixed drug eruption (FDE) is a distinct drug induced reaction
pattern that characteristically recurs at the same skin or the mucosal site.
The pathogenetic mechanism underlying FDE is still enigmatic. The most
commonly accepted hypothesis is persistence of memory T cells in the
affected skin which is evident as increased ICAM-1 expression in the
lesional skin. CD8+ cells phenotypically resembling effector memory T
cells have been shown to be greatly enhanced in the lesions of FDE.  129
The drugs that commonly cause mucosal FDE include co-
trimoxazole, oxyphenbutazone, and tetracycline.130
The lesions of FDE usually start as an erythematous macule that
subsequently evolves into a plaque. Vesicles and bullae develop at a later
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stage and are usually hemorrhagic. The lesions can occur on any part of
the skin and mucous membranes. The sites of predilection are the limbs,
sacral region, genitalia, palmar and plantar skin.131
The oral mucosa may be involved in association with skin lesions
or alone. Classically the transitional epithelium of the mucocutaneous
junctions is involved. Systemic manifestations are uncommon and
include fever, malaise, nausea, diarrhoea, abdominal pain, urethritis, and
conjunctivitis. 131
Microscopy: The  histological  changes  are  similar  to  erythema
multiforme and toxic epidermal necrolysis. Necrotic keratinocytes with
an eosinophilic cytoplasm and a pyknotic nucleus in the epidermis and
pigment incontinence due to hydropic degeneration of the basal cell layer
in the dermis are present.1
Aim of the Study
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    AIM OF THE STUDY
? To study the various acquired bullous dermatoses causing oral
lesions
? To study the age distribution
? To study the sex distribution
? To study the intra oral distribution of lesions
?  To study the evolution of the oral lesions with regard to the skin






            Single centred hospital based cross sectional study
Study period:
            October 2009 to September 2011
Sample size:
           Two hundred and fifty two patients
Data collection:
          Proforma based
Inclusion criteria:
? Patients of acquired vesiculobullous disorders of all ages and both
sex with active disease.
Exclusion criteria:
? Patients who have undergone treatment and those with inactive
disease as evidenced by absence of lesions during the study period
? Patients who are unwilling to get included in the study
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All patients with acquired vesiculobullous disorders who attended the
out patient division of Dermatology department, Rajiv Gandhi
Government General Hospital, Chennai from October 2009 to September
2011 were  screened for oral lesions and detailed history was taken.
Patients were enquired regarding the onset, duration of the disease,
the evolution of the lesions, whether the oral lesions preceded or followed
or appeared at the same time with the skin lesions and any drug intake
prior to the onset of the lesions. Precipitating or aggravating factors were
noted. History of constitutional symptoms, loss of weight and appetite,
melena, urticarial weals, pruritus, photosentivity, abdominal pain,
diarrhoea, constipation, joint pain, symptoms of the oral lesions, previous
similar episodes were noted. Other coexisting diseases if present, were
documented.
Personal history regarding diet, other associated diseases and
treatment history were noted. Family history of similar skin disease was
taken.
All patients were subjected to routine clinical examination
including general, systemic and dermatological examinations. The
morphology and distribution of the lesions in the skin and oral cavity
were recorded. Clinical signs (Nikolsky’s sign, bulla spreading sign) were
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elicited in the respective patients. The extent of oral lesion in patients
with  pemphigus  vulgaris  was  rated  using  3  grades  as  follows:  Grade  I  -
Only 1 site  is  involved;  Grade II  -  2 sites  are involved;  Grade III  -  3 or
more sites are involved.
Investigations including Tzanck smear, routine blood parameters,
urine  examination,  chest  x-ray,  etc  were  done.   Biopsies  (skin/  oral
mucosal biopsy/ both) were done in appropriate patients. Patients with
oral lesions in sites other than the lips, were taken to the Department of
Oro maxillo facial surgery, Government Dental College and Hospital,
Chennai for biopsy. Direct immunofluorescence study was done only in
selected patients (patients with oral lesions alone, discordant skin &
mucosal biopsy results) because of cost constraints and lack of feasibility.
Serological confirmation was done only in patients with primary episodes
of herpes simplex by HSV IgM Elisa technique. Viral culture in vero cell
lines was done for the first 25 oral herpes simplex patients for
confirmation. For the rest of the patients, serology and culture were not





            Out of the total 87,429 patients who attended the dermatology
OPD during the study period, 252 patients were acquired vesiculobullous
dermatoses (0.29%). Among these, 126 were viral infections, 114 were
autoimmune bullous dermatoses and 12 were drug induced. Of the total
252 patients, oral lesions were present in 175 patients (69.4%). Among
the 126 patients with viral infections, 92 had oral lesions (73%). Among
the autoimmune group, 72 out of 114 patients had oral lesions (63.2%).
Of the 12 patients in the drug induced group, 11 had oral lesions (91.7%).







24 2 3 29 11.5%
21-30
years
25 11 4 40 15.9%
31-40
years
28 25 3 56 22.2%
41-50
years
19 32 0 51 20.2%
51-60
years
14 16 2 32 12.7%
61-70
years
12 23 0 35 13.9%
>71 years 4 5 0 9 3.6%
Total 126 114 12 252 100%
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       The age distribution varies from 2 years to 73 years (mean - 35.98) in
the viral group, 17 to 85 years in the autoimmune group (mean - 47.18)
and 16 to 60 years (mean - 31.58) in the drug induced group. In the first
decade, viral infections were more common than the autoimmune
dermatoses.
Sex distribution:
The gender wise distribution varies as given in the table 2.
Overall,  there  were  148  females  and  104  males  (M:F-  1:1.4).  Viral
infections showed a male to female ratio of 1 : 1 (64:62) whereas in the
autoimmune group, it was 1:4 (33:81). In the drug induced group, there
was a slight male predominance (1.4 : 1) with 7 males and 5 females.
Table 2. SEX DISTRIBUTION OF THE TOTAL PATIENTS
Sex Viral Autoimmune Druginduced Total Percentage
Male 64(50.8%) 33(28.9%) 7(58.3%) 104 41.3%
Female 62(49.2%) 81(71.1%) 5(41.7%) 148 58.7%
Total 126 114 12 252 100%






















VIRAL INFECTIONS  (Table 3) :
.           Viral  infections  constituted  the  major  part  of  the  acquired
vesiculobullous dermatoses (50%). Various viral infections and their
relative proportion are shown in the table 3. Herpes simplex was the most
common viral infection constituting about 77.1% of the total patients
followed by varicella zoster virus (19.8%) infection.









pox 0 4 4 3.1%
Herpes
zoster 3 18 21 16.7%
Hand, foot and
mouth disease 2 2 4 3.1%
Total 92 34 126 100%
Age distribution (Table 4):
             Majority of the viral infections were seen in 4th decade (21.4%)
followed by 3rd decade (19.8).
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0-10 1 1 0 0 1 0 2 2 7 5.6%
11-20 17 0 0 2 0 0 0 0 19 15.1 %
21-30 23 1 0 1 0 0 0 0 25 19.8%
31-40 21 4 0 0 1 1 0 0 27 21.4%
41-50 14 3 0 0 0 4 0 0 21 15.1%
51-60 5 0 0 1 1 5 0 0 12 11.1%
>60 7 0 0 0 0 8 0 0 15 11.9%
Total 88 9 0 4 3 18 2 2 126 100%
Herpes simplex was seen in all age groups while herpes zoster was
less  common  before  the  3rd decade. Hand, foot & mouth disease was
exclusively seen in the first decade.
Sex distribution (Table 5):
The total number of males was almost equal to that of females (64 :
62).  The  sex  distribution  was  1:1.  There  was  no  sex  predilection  as  a
whole as well as in any of the individual viral infection.
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41 7 46 3 97
Chicken pox 0 3 0 1 4















Among the 97 patients of herpes simplex, 87 patients had isolated
oral involvement, 6 had isolated nasal mucosal involvement and 3 had
isolated genital mucosal involvement. One patient had both nasal and oral
mucosal involvement. Only 3 of the patients with oral lesions had
primary episode (confirmed by culture and HSV IgM ELISA) while the
rest of them had recurrent episodes. All the three primary episode patients
were found to be positive for HSV 1 antibodies. Two patients had
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          Of  the  87  patients  with  oral  herpes,  3  were  primary  herpetic
gingivostomatitis, 2 were recurrent intraoral herpes simplex and the rest
of them (82) were recurrent herpes labialis. Lips were the predominant
site affected, seen in 85 patients (97.7%). Tongue was involved in all the
3 primary herpetic gingivostomatitis and 2 recurrent intraoral herpes
patients (5.7%). Palate was involved in 2 of the 5 patients with primary
episode (2.3%). Gingiva was the least to get involved (1.1%). Meningitis
was encountered in one case.
Chicken pox/ Varicella & Herpes zoster:
           None of the four patients of Varicella had enanthem. Out of the 21
patients with herpes zoster, oral lesions were found in 3 of them (14.3%).
Ramsay Hunt syndrome with lower motor neuron facial palsy and
vesicles in the ipsilateral pinna & tongue was present in two patients and
maxillary zoster involving left half of the palate and upper labial mucosa
was seen in one patient.
Hand, foot and mouth disease:
Of the 4 patients seen, two patients had oral lesions. Tongue was
the site of involvement in one while lips were involved in the other.
PRIMARY HERPETIC GINGIVOSTOMATITIS
RECURRENT INTRAORAL HERPES SIMPLEX
RECURRENT HERPES LABIALIS WITH NASAL
INVOLVEMENT
MULTINUCLEATED EPITHELIAL GIANT CELLS
UNINFECTED VERO CELL LINES
HSV CULTURE – CYTOPATHIC EFFECTS
(MULTINUCLEATED CELLS)
MAXILLARY HERPES ZOSTER INVOLVING THE LIPS
VESICLES AND EROSIONS IN THE PALATE IN
MAXILLARY HERPES ZOSTER
RAMSAY HUNT SYNDROME
 VESICLES IN THE PINNA AND CHEEK
VESICLES AND EROSIONS IN THE LIPS AND TONGUE WITH
DEVIATION OF ANGLE OF MOUTH
RAMSAY HUNT SYNDROME - DEVIATION OF ANGLE OF
THE MOUTH
HAND, FOOT AND MOUTH DISEASE
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AUTOIMMUNE VESICULOBULLOUS DISORDERS:
Out of the 114 patients, pemphigus vulgaris was the most common
dermatoses (59.7% of the total patients). Among the total of 114, 72
patients had oral mucosal involvement among which pemphigus vularis
was most common (84.7%) followed by bullous pemphigoid (8.3%)
(Table 6).






Pemphigus vulgaris 61(84.7%) 7 (16.7%) 68 (59.7%)
Pemphigus
vegetans 3 (4.2%) 0 (0%) 3 (2.6%)
Pemphigus
foliaceous 0 (0%) 11 (26.2%) 11 (9.6%)
Pemphigus
erythematosus 0 (0%) 6 (14.3%) 6 (5.3%)
Bullous
pemphigoid 6 (8.3%) 16 (38.1%) 22 (19.3%)
Dermatitis
herpetiformis 2 (2.8%) 2 (4.7%) 4 (3.5%)
Total 72 (63.2%) 42 (36.8%) 100%
Age distribution:
The age distribution of various autoimmune bullous disorders has
been tabulated (Table 7).
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The  age  distribution  varies  from  17  to  85  years  (mean  -  47.18).
Pemphigus vulgaris was most commonly seen in 4th decade followed by
5th decade (mean - 43.45). Bullous pemphigoid was more common in the
seventh followed by sixth decade ranging from 24 to 85 years (mean -
57.54).   All  the  3  patients  with  pemphigus  vegetans  were  in  the  5th
decade.



























oral 2 10 16 15 11 6 1 0 68
Without




oral 0 0 0 3 0 0 0 0 3Without




oral 0 0 0 0 0 0 0 0 11Without




oral 0 0 0 0 0 0 0 0 6Without




oral 0 1 1 1 2 0 1 1 22Without




oral 0 0 1 1 0 0 0 0 4Without
oral 0 0 0 0 0 2 0 0
Total 2 11 25 32 23 16 4 1 114
Sex distribution (Table 8):
The sex distribution in the autoimmune bullous dermatoses is
tabulated. Overall, females were the most affected (M:F- 1 : 2.4). In
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pemphigus vulgaris, the difference was more marked (M:F – 1: 3.9)
whereas  in  bullous  pemphigoid,  it  was  less  marked  (M:F  –  1  :  1.4).  In
pemphigus foliaceous (M:F – 1: 1.8) and pemphigus erythematosus (M:F
– 1: 5), there was a predilection for females. Dermatitis herpetiformis was
exclusively seen in males.














13 1 48 6 68
Pemphigus
vegetans
1 0 2 0 3
Pemphigus
foliaceous
0 4 0 7 11
Pemphigus
erythematosus
0 1 0 5 6
Bullous
pemphigoid
2 7 4 9 22
Dermatitis
herpetiformis
2 2 0 0 4
Total 18 15 54 27 114
Oral cavity involvement:
          Oral  lesions  were  seen  in  61  out  of  the  68  patients  of  pemphigus
vulgaris (89.7%) whereas in bullous pemphigoid, it was present in 6 out
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of the 22 patients (27%). None of the pemphigus foliaceous and
pemphigus erythematosus group had oral lesions. All the 3 pemphigus
vegetans  patients  had  oral  lesions  (100%).  2  out  of  the  4  dermatitis
herpetiformis (50%) patients had oral lesions.
Site of involvement in the oral cavity:
Buccal mucosa (72%) was the most common site involved in
pemphigus vulgaris followed by the labial mucosa (69%). In bullous
pemphigoid, buccal mucosa (83.3%) followed by gingiva (50%) were the
commonest sites involved. Among the total 6 patients, 3 had isolated
buccal mucosal involvement, 2 had both gingival and buccal mucosal
involvement and 1 patient presented with isolated desquamative
gingivitis. Of the two DH patients with oral lesions, lips were involved in
both while tongue was involved in one of them.
Morphology of oral lesions:
Erosions were predominant in the pemphigus vulgaris patients
(93.4%). Intact vesicles/bullae were seen only in 4 patients (6.5%)




AGE DISTRIBUTION OF PEMPHIGUS VULGARIS
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PREDOMINANT SITE OF ORAL

















ORAL GENITAL NASAL CONJUNCTIVA
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Initial site of involvement in the oral cavity:
Buccal mucosa was the most common site to get involved first in
the oral cavity (44.3%) followed by lips (31.1%) and tongue (18%) in
pemphigus vulgaris. Gingiva and buccal mucosa were the first to get
affected in 50% each of the patients with bullous pemphigoid.
Table 9. Initial site of involvement in the oral cavity.
Lips Buccal
mucosa
Tongue Palate Gingiva Pharynx Total
Pemphigus
vulgaris
19 27 11 2 0 2 61
Pemphigus
vegetans
1 2 0 0 0 0 3
Bullous
pemphigoid
0 3 0 0 3 0 6
Dermatitis
herpetiformis
2 0 0 0 0 0 2
Total 22 32 11 2 3 2 72
Extent of oral lesions:
Among the 61 patients with oral lesions, 35 patients (57.4%) had
Grade  III  involvement  of  the  oral  cavity  followed  by  Grade  II
involvement in 19 patients (31.1%) and  Grade 1 in 7 patients (11.5%).
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Onset of the lesions in skin and oral cavity (Table 10):
Of the 61 patients of pemphigus vulgaris with oral lesions, 8
patients had only oral lesions without skin involvement. Among the
remaining 53 patients, oral involvement preceded the onset of skin
lesions in 33 patients (62.3%) while skin involvement preceded the onset
of oral lesions in 10 patients (18.7%) and in the remaining 10 patients
(18.7%), both had simultaneous onset.


















vulgaris 10 33 36.6 days 10 145.7 days
Bullous
pemphigoid 0 2 120 days 4 52.5 days
Pemphigus




0 0 - 2 630 days
Total 11 14 37
The average time interval between the onset of oral and skin
involvement in those with first involvement in the oral cavity was 36.6
days whereas in those with first involvement in the skin was 145.6 days.
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Among the 3 pemphigus vegetans patients, 2 patients had lesions in
the oral cavity first and 1 had simultaneous onset of skin & oral lesions.
Among the 6 patients with bullous pemphigoid, oral mucosa was first
affected in 2 patients with an average time interval of 120 days.
Superinfection with candida (Table 11):
Of the total 61 patients of pemphigus vulgaris, 53 patients
(86.9%) had candidal superinfection whereas none of the bullous
pemphigoid, pemphigus vegetans and Dermatitis herpetiformis patients
had candidiasis. This was a statistically significant association (P value –
0.0001).




Pemphigus vulgaris 53 8 61
Bullous pemphigoid 0 6 6
Pemphigus vegetans 0 3 3
Dermatitis herpetiformis 0 2 2
PEMPHIGUS VULGARIS - FLACCID VESICLES AND
EROSIONS
PEMPHIGUS VULGARIS - FLACCID VESICLES AND
EROSIONS
PEMPHIGUS VULGARIS - EROSIONS OVER LIPS
PEMPHIGUS VULGARIS -EROSIONS OVER
BUCCAL MUCOSA
PEMPHIGUS VULGARIS -PALATAL EROSIONS
PEMPHIGUS VULGARIS - EROSIONS OVER
FLOOR OF THE MOUTH
PEMPHIGUS VULGARIS - EROSIONS IN THE TONGUE




CEREBRIFORM TONGUE IN PEMPHIGUS
VEGETANS
BULLOUS PEMPHIGOID - INTACT BULLA IN
BUCCAL MUCOSA
INTACT BULLA IN BULLOUS PEMPHIGOID-
SUBLINGUAL AREA
DESQUAMATIVE GINGIVITIS IN BULLOUS PEMPHIGOID
ACANTHOLYTIC CELLS OF PEMPHIGUS VULGARIS
HPE- SUPRABASAL BULLA IN BUCCAL MUCOSA (10X)
HPE- SUPRA BASAL BULLA (40X)
HPE- SUPRABASAL SEPARATION IN LABIAL MUCOSA (10X)
HIGH POWER VIEW (40X) – Acantholytic cells &
Intact basal cell layer
HPE- SUPRABASAL BULLA IN TONGUE (10x)
HPE- SUPRABASAL BULLA IN TONGUE (40x)
HPE-PEMPHIGUS VEGETANS WITH HYPERPLASTIC
EPITHELIUM AND SUPRABASAL SEPARATION (10X)
PEMPHIGUS VEGETANS (40X)




DIRECT IMMUNOFLUORESCENCE STUDY IN PEMPHIGUS
VULGARIS- FISH NET PATTERN
DIRECT IMMUNOFLUORESCENCE STUDY IN PEMPHIGUS
VEGETANS- FISH NET PATTERN
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Clinical and histopathological (oral mucosal biopsy) correlation:
             Out of the 53 skin biopsy proven patients of pemphigus vulgaris
with both skin and oral involvement, typical suprabasal cleavage was
seen in 50 patients in oral biopsy (94.3% correlation). Intraepidermal
cleavage  was  seen  in  2  patients  and  in  the  remaining  1  case,  the  biopsy
had non-specific. In all these 3 patients, the mucosal biopsy specimen
were subjected to direct immunofluorescence study and were confirmed
as pemphigus.
In pemphigus vegetans and bullous pemphigoid, the correlation
was 100% with respect to the level of cleavage. In both the two patients
with Dermatitis herpetiformis, the oral mucosal biopsies did not correlate
with the skin biopsy findings. The direct immunofluorescence of the
mucosal biopsy specimen were also negative.
DRUG INDUCED VESICULOBULLOUS DERMATOSES:
Among the total 252 patients, 12 patients were drug induced
vesiculobullous dermatoses. The various patterns, their age and sex
distribution are tabulated (Table 12).
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Table -12. Drug induced vesiculobullous dermatoses.
Age
(years)


























<20 1 0 2 0 0 0 0 0 3
21-30 2 0 0 0 2 0 0 0 4
31-40 0 0 0 0 2 0 0 1 3
41-50 0 0 0 0 0 0 0 0 0
51-60 1 0 1 0 0 0 0 0 2
Total 4 0 3 0 4 0 0 1 12
             About 83.3% of the patients (10 of the 12 patients) were below
forty years of age. The mean age for EM was 31.75 years, 29.75 years for
Toxic epidermal necrolysis (Range: 23 – 32 years) and 31 years for
Stevens Johnson syndrome (Range: 18 – 58 years).
Sex distribution:
Totally there were 7 male and 5 female patients. The male to
female ratio was 1.4 : 1. The male to female ratio of EM was 1:3 and that
of TEN was 1:3 whereas in SJS, it was 2:1.
Oral mucosal involvement (Table 14):
Lips were the most common sites involved (100%) followed by
tongue (30%).
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Table 14: Oral mucosal involvement
Lips Buccalmucosa Tongue Palate
EM 4 2 2 0
SJS 3 0 0 1
TEN 3 0 1 1
Total 10 2 3 2
Onset of lesions in the skin & oral cavity:
Among the 11 patients with both skin and oral mucosal
involvement, oral lesions were the first to get involved in 8 patients
(72.8%) followed by skin involvement in 2 patients (18.2%) and 1 patient
had simultaneous involvement of both (9%). The average time interval
between the onset of oral and skin lesions among those who had first
involvement in the oral cavity was 2 days and for those who had skin
involvement first, it was 1 day.
Offending agent (Table 13):
Dermatoses Drugs
EM Phenytoin, Amoxycillin, Cephalexin.
SJS Cefotaxime, Diclofenac, Cotrimoxazole.
TEN NSAIDS, Diclofenac, Carbamazepine (two patients).
FDE Paracetamol.






















ONSET OF LESIONS IN THE SKIN AND ORAL





ORAL ERYTHEMA MULTIFORME- SWELLING OF LIPS WITH
HEMORRHAGIC CRUSTING
STEVENS-JOHNSON SYNDROME





Acquired vesiculobullous dermatoses constituted 0.29% of the total
OPD patients. Among these, oral lesions were seen in 69.4% of the
patients. In the study conducted by Nada M. Suliman et al132 done in 544
patients in Sudan, oral lesions were seen in 72.2% of the patients which is
comparable to our study.
          Viral infections formed the major part of the vesiculobullous
dermatoses, constituting about 50% followed by autoimmune dermatoses
(45%). In the same study of Nada M. Suliman et al, viral infections and
autoimmune dermatoses constituted 31.2% and 65.6% of the total
vesiculobullous dermatoses respectively.132 This variation can be
explained by the difference in patients’ willingness to seek medical care
for a common ailment like recurrent herpes labialis which can alter the
prevalence in hospital based studies.
VIRAL INFECTIONS:
          Herpes simplex was the most common viral infection found among
the patients of vesiculobullous dermatoses (77% of the total viral
infections) followed by varicella zoster virus (19.9%) infection while




Majority of the viral infections were seen before the 4th decade of
life (61.9%).  Herpes simplex was seen in all age groups with peak values
in the 3rd and  4th decade. Mean age was 34.9 years in males and 29.02
years in females. About 70% of herpes simplex patients were seen in <40
years of age in consistence with the Hashido et al study.133
Twenty out of the 21 patients with herpes zoster (95.2%) were
above 40 years of age (Mean – 53.85 years). Gonzaga et al have reported
a similar  occurrence of  majority of  the patients  being above 40 years of
age.134 The mean age for herpes zoster reported by Oh et al was 50.35
years.135 Hand,  foot  &  mouth  disease  was  exclusively  seen  in  the  first
decade ranging from 2 – 10 years (Mean – 8 years) whereas Sarma et al
have reported exclusive occurrence of the disease in 1 to 12 years age
group136 and C. H. Tay et al have reported >90% occurrence of the
disease among children in the first decade.137
Sex:
There was no gender predominance as a whole or in any of the
individual viral infections. Heininger et al have reported similar
observation in varicella138 while Shetty et al have documented a male to
female ratio of 7:1 which has been attributed by them to an outbreak in a
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boy’s school during their study period.139 While Sarma et al have
reported a slight predilection for males in their study on hand, foot and
mouth (M:F- 1.2:1), 136 C. H. Tay et al have reported an equal
distribution.137
Oral lesions:
In Herpes simplex, lips were the predominant sites to be involved,
seen in 85 patients (97.7%). Tongue was involved in all the primary and
recurrent intraoral herpes patients (5.7%). Gingiva was the least to get
involved (1.1%).
None of the 4 patients of Varicella had enanthem. Kolokotronis et
al have reported 74% of a total 62 patients with mucosal lesions.140 As
our study had only a small group, comparison cannot be done. Out of the
21 herpes zoster patients, oral lesions were found in 3 of them (14.3%).
Maxillary branch was involved in one patient (4.8%) with vesicles over
left  half  of  the  palate  and  upper  labial  mucosa.  In  the  study  done  by
Latheef et al, maxillary branch involvement was seen in 7.3% of the total
205 herpes zoster patients,141 compared to only 1 out of 21 (4.8%)
patients in this study. Ramsay Hunt syndrome with lower motor neuron
facial palsy and vesicles in the ipsilateral pinna & tongue was found in
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two patients (9%) whereas in the study conducted by Thappa et al in 107
patients, only one case was reported (0.9%).142
Of the 4 patients of Hand, foot & mouth disease seen, two patients
had oral lesions (50%). Tongue was involved in one patient and lips in
the other. This differs from the Sarma et al study  in which 86.8% of the




          About 52.9% of the patients were in the 4th (27.9%) and 5th decade
(25%) in our study (average – 43.45 years). In the study conducted
by Thorakkal Shamim et al in Calicut, the mean age was 42.73 years143
while  in  the  Esmaili  N  et  al  study,  the  mean  age  at  the  time  of
presentation was 41.5 years144 which were all almost similar to this study.
Sex distribution:
           Females were most affected in our study (M : F – 1 : 3.9). The
difference is slightly higher when compared to the studies done by
Alonso  et  al  (male  to  female  ratio  of  1  :  2.5),28 Langan  et  al  (male  to
female ratio was1:2),145 Esmaili  N  et  al  (male  to  female  ratio  of
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1 : 1.59)144 and Deval Vora et al (male to female ratio of 1 : 1.48 in South
India).146
Mucosal involvement:
Oral cavity was the most affected mucosa (89.7% of pemphigus
vulgaris patients) followed by genital (20.6%), nasal mucosa (11.8%) and
conjunctiva (2.9%) in concurrence with the Deval Vora et al study.146
Oral cavity involvement:
           Oral lesions were seen in 61 out of the 68 patients of pemphigus
vulgaris (89.7%) of which 53 patients (78%) had both skin and oral
lesions, 7 (10.3%) had only skin lesions and 8 (11.7%) had only oral
lesions whereas in the Esmaili N et al study, 67.9% of patients had both
skin and oral involvement, 6.4% of patients had only skin lesions and oral
involvement was exclusively seen in 25.7% of the patients.144
Abdolsamadi et al have reported isolated oral involvement in 47% of
their patients.147 These studies were conducted in dental OPDs, to which
patients tend to attend when there are no skin lesions and hence have
reported a higher prevalence.
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Morphology of oral lesions:
Erosions were predominantly seen in 93.4% of our patients, while
rest of them showed both erosions as well as few vesicles, similar to the
observation made by Alonso et al who have reported that 92.8% of their
patients had erosions.28
Site of involvement in the oral cavity:
Buccal mucosa was the commonest site to get affected (44.3%)
followed by lips, palate and tongue similar to the study conducted by
Thorakkal Shamim et al 143 whereas in the study conducted by Robinson
et al, majority of oral lesions were in the gingival.148 In the Laskaris et al
study, majority of lesions were in the palate.149
Extent of oral lesions:
About 35 patients (57.4%) had Grade III involvement of the oral
cavity followed by Grade II (19 patients, 31.1%) and  Grade 1 (7 patients,
11.5%) similar to the observation made by Thorakkal Shamim et al 143
and the Alonso et al in their studies.28
Onset of the lesions in skin and oral cavity:
The most common initial localization of the disease was the oral
cavity, seen in 41 patients (60.3%), followed by skin in 17 patients (25%)
65
and simultaneous onset of both in 10 patients (14.7%). This observation
is  similar  to   the  study  done  by  Ameneh  Yazdanfar  et  al150 where oral
lesions were the first to get involved in 60% patients and approximately
coincides with the Thorakkal Shamim et al study in which the
corresponding values are 53.52%, 23.94% and 22.53% respectively.143 In
the  study  done  by  Ali  et  al  in  the  central  Iran,  oral  mucous  membrane
involvement was the first to get involved in 74% of the patients.151
Candidal superinfection:
About 86.9% of patients with oral lesions had secondary oral
candidiasis confirmed by the presence of pseudohyphae and spores in the
10% KOH mount. In the Chmurova et al study, only 45.2% (14 out of 31)
were found to have candidal superinfection.152 This higher incidence is
due to  poor oral hygiene, as the painful nature of the lesions hinders in
maintaining good hygiene and secondary to the use of steroids and
antibiotics for treatment. This has to be taken care of during the
management of oral pemphigus.
Clinical and histopathological correlation:
          Out of the 53 skin biopsy proven patients of pemphigus vulgaris
with both skin and oral involvement, typical suprabasal cleavage,
acantholytic cells were seen in 50 patients in oral biopsy (94.3%
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correlation with skin biopsy). Intraepithelial blisters with acantholytic
cells  were  seen  in  52  patients  (98%)  compared  to  100%  in  the  study
conducted by Alonso et al.28
Bullous pemphigoid:
Age:
Majority of the bullous pemphigoid patients were seen in 6th and 7th
decades. This coincides with the study conducted by Budimir et al in
which most of the patients were between 70 – 90 years age group.153
Sex:
There was no sexual predilection was seen in this study which is in
similar to the study done by Budimir et al.153
Oral cavity involvement:
Oral cavity involvement was seen in 6 out of the 22 (27%) patients
and is slightly higher than the study conducted by Budimir et (17%)153
and Chang et al (12.8%).154 In  the  study  done  by  Arambašin  et  al,  oral
mucosal involvement was seen in 40% which supports our study.69
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Site of involvement in the oral cavity:
            Buccal mucosa (83.3%) followed by gingiva (50%) were the
commonest sites to be involved similar to the observation made by
Budimir et al in their study.153
 Onset of the lesions in skin and oral cavity:
Two patients had their first involvement of the disease in the oral
cavity  (9%)  compared  to  5% in  the  Budimir  et  al  study.153 None  of  the
patients had isolated mucosal involvement in both studies.
DRUG INDUCED VESICULOBULLOUS DERMATOSES:
           Among the total 12 patients, 4 had erythema multiforme, 3 had
Stevens Johnson syndrome, 4 had Toxic epidermal necrolysis and 1 had
bullous FDE. All the patients had history of drug intake prior to the onset
of lesions. One patient was on Etoposide and Ifosfamide which has not
been reported in the literature to cause EM.
Age:
Out of the 12 patients, 10 patients (83.3%) were below forty years
of  age.  The  mean  age  for  EM  was  31.75  years  which  concurs  with  the
study done by Goncalves et al in which majority of EM patients in 20-40
years age group.155 The mean age for Toxic epidermal necrolysis was
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29.75 years (Range: 23 – 32 years) and 31 years for Stevens Johnson
syndrome (Range: 18 – 58 years) similar to the Sanmarkan et al study, in
which maximum number of SJS/TEN patients were in the age group of
11-30 years.156 Schöpf et al reported a mean age of 25 years in TEN
which is similar to our study.157
Sex:
The male to female ratio of the total patients was 1.4:1. The male
to female ratio of EM was 1:3. In the Goncalves et al study, females were
the most affected (62%).155 The male to female ratio was 1:3 for TEN and
2:1  for  SJS.  In  the  Schöpf  et  al  study,  the  corresponding  values  are  1:2
and 2:1 which are almost similar.157 Similar findings were observed in the
Sanmarkan et al study.156
Oral mucosal involvement:
The oral cavity was involved in 11 out of the 12 patients (91.7%).
Lips were the most frequently involved sites, seen in 100% of the patients
with oral lesions, followed by the tongue (30%). Among the patients with
EM in this study, oral lesions were seen in all patients while Goncalves et
al reported only 33% of patients with oral involvement.155
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Offending drugs:
NSAIDs were the most common drugs precipitating the disease in
4 out of the total 12 patients (33.3%). The drugs most commonly
involved were antibiotics in SJS (67%) followed by analgesics (33%).
For TEN, analgesics and antiepileptics were the offending agents,





1. Acquired vesiculobullous dermatoses constituted 0.29% of the total
patients attending Dermatology OP division and 69.4% of them
had oral involvement.
2. Viral infections are the most common subdivision of
vesiculobullous dermatoses. Majority of the viral infections were
seen before the 4th decade of life. No sex predilection was seen as a
whole or in any of the individual viral infections. Lips were the
most common sites to get involved in viral infections.
3. Herpes simplex was the most common viral infection found mainly
in <40 years of age while herpes zoster was seen above 40 years of
age.
4. Autoimmune bullous disorders constituted 45.2% of the total
patients and 63.2% of these patients had oral lesions. The age
distribution varied from 17–85 years. The male to female was 1:
2.4.
5. Pemphigus vulgaris was the most common autoimmune bullous
dermatoses followed by bullous pemphigoid. Pemphigus vulgaris
was most commonly seen in 4th decade followed by 5th decade
while bullous pemphigoid was more common in the seventh
followed by sixth decade. Oral mucosal involvement was seen in
89.7% of pemphigus vulgaris and 27% of bullous pemphigoid
patients.
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6. The male to female ratio was 1 : 3.9 in pemphigus vulgaris and 1 :
1.4 in bullous pemphigoid.
7.  Buccal mucosa was the most common site to get involved in both
pemphigus vulgaris and bullous pemphigoid. Isolated oral mucosal
involvement was found in 11.8% of patients with pemphigus
vulgaris. The oral lesions preceded the onset of skin lesions in
62.3% of patients and the average time interval between the onset
of each was 36.6 days.
8. Early diagnosis can be made by biopsy of the oral lesions in
autoimmune vesiculobullous dermatoses in those patients with first
involvement in the oral mucosa.
9. Drug induced vesiculobullous dermatoses constituted 4.8% of the
total patients. Antimicrobials and analgesics were the most
common  offending  agents.  Majority  of  the  patients  were  below
forty years of age. The male to female ratio was 1.4:1.
10. The oral cavity was involved in 91.7% of the patients. Lips were
the most frequently involved sites seen in 100% of the patients
with oral lesions.
11. Early diagnosis and prompt treatment will help reducing the
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z 34 F HS 4 days R P A P A A A A A Nil Nil Neg HSV 1
2 9 M HS 1 day P P A A P A A P A Nil Nil MNG  HSV 1
3 35 F HS 3 days R A A P A A A A A Nil Nil Neg HSV 1
4 42 M HS 2 day R A A P A A A A A Nil Nil MNG  HSV 1
5 28 M HS 2 days R A P P A A A A A Nil Nil MNG  HSV 1
6 24 F HS 3 days R A A P A A A A A Nil Nil MNG  HSV 1
7 33 F HS 4 days R P A P A A A A A Nil Nil Neg HSV 1
8 22 M HS 5 days R A A P A A A A A Nil Nil Neg HSV 1
9 32 F HS 2 days R P P A A A A A A Nil Nil MNG  HSV 1
10 29 F HS 3 days R A A P A A A A A Nil Nil MNG  HSV 1
11 30 M HS 3 days R A A P A A A A A Nil Nil Neg HSV 1
12 43 M HS 2 days R A A P A A A A A Nil Nil MNG  HSV 1
13 21 F HS 2 days R P A P A A A A A Nil Nil MNG  HSV 1
14 17 M HS 2 days R A A P A A A A A Nil Nil MNG  HSV 1
15 22 F HS 2 days R A A P A A A A A Nil Nil Neg HSV 1
16 14 M HS 7 days P P A A P P A A A Nil Meningitis MNG  HSV 1
17 27 M HS 3 days R P A P A A A A A Nil Nil MNG  HSV 1


































































































































































































19 18 F HS 2 days R A A P A A A A A Nil Nil MNG  HSV 1
20 42 M HS 5 days R P A P A A A A A Nil Nil Neg HSV 1
21 8 M HS 2 days P P A P P P A A A Nil Nil MNG  HSV 1
22 27 M HS 4 days R A A P A A A A A Nil Nil MNG  HSV 1
23 26 F HS 3 days R P A P A A A A A Nil Nil Neg HSV 1
24 29 M HS 2 days R A P P A A A A A Nil Nil Neg HSV 1
25 32 F HS 2 days RIOH P A P P A A A A Nil Nil MNG  HSV 1
26 52 M HS 1 day R A A A A A A A A Nasal Nil Neg HSV 1
27 57 M HS 2 days R A A A A A A A A Nasal Nil MNG  HSV 1
28 46 M HS 2 days R A A A A A A A A Nasal Nil MNG  HSV 1
29 28 M HS 3 days R A A A A A A A A Genital Nil Neg Not done
30 19 M HS 3 days R A P P A A A A A Nil Nil MNG  Not done
31 31 F HS 2 days R A A P A A A A A Nil Nil MNG  Not done
32 14 M HS 4 days R A A P A A A A A Nil Nil MNG  Not done
33 31 F HS 3 days R P A P A A A A A Nil Nil MNG  Not done
34 35 F HS 2 days R P P A A A A A A Nasal Nil Neg Not done
35 35 F HS 2 days R P A P A A A A A Nil Nil MNG  Not done



















































































































37 38 M HS 3 days R P P A A A A A A Nasal Nil Neg Not done
38 18 F HS 4 days R A A P A A A A A Nil Nil MNG  Not done
39 30 M HS 2 days R A A P A A A A A Nil Nil Neg Not done
40 21 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
41 25 F HS 3 days R A A P A A A A A Nil Nil Neg Not done
42 31 M HS 2 days R P A P A A A A A Nil Nil MNG  Not done
43 20 M HS 6 days R P A P A A A A A Nil Nil Neg Not done
44 18 F HS 2 days R A P P A A A A A Nasal Nil Neg Not done
45 45 F HS 5 days R A A P A A A A A Nil Nil Neg Not done
46 29 M HS 3 days R P P P A A A A A Nil Nil MNG  Not done
47 47 M HS 4 days R A A P A A A A A Nil Nil Neg Not done
48 52 F HS 3 days R P A P A A A A A Nil Nil MNG  Not done
49 45 F HS 2 days R P A P A A A A A Nil Nil Neg Not done
50 42 M HS 3 days R P A P A A A A A Nil Nil MNG  Not done
51 13 F HS 2 days R P A P A A A A A Nil Nil MNG  Not done
52 31 M HS 2 days R P A P A A A A A Nil Nil MNG  Not done
53 24 F HS 2 days R A A P A A A A A Nil Nil Neg Not done



















































































































55 19 M HS 2 days P P A P A A A A A Genital Nil MNG  Not done
56 12 F HS 4 days R
bilateral
A P P A A A A A Nil Nil Neg Not done
57 32 F HS 5 days R A A P A A A A A Nil Nil Neg Not done
58 32 F HS 5 days R A A P A A A A A Nil Nil Neg Not done
59 33 F HS 3 days R A A P A A A A A Nil Nil MNG  Not done
60 25 F HS 3 days R A A P A A A A A Nil Nil Neg Not done
61 54 M HS 2 days R A A P A A A A A Nil Nil MNG  Not done
62 34 M HS 2 days R A A P A A A A A Nil Nil MNG  Not done
63 17 F HS 3 days R A A P A A A A A Nil Nil Neg Not done
64 55 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
65 50 F HS 3 days R A A P A A A A A Nil Nil Neg Not done
66 21 M HS 3 days R A A P A A A A A Nil Nil Neg Not done
67 44 F HS 2 day R A A P A A A A A Nil Nil MNG  Not done
68 73 M HS 2 days R A A P A A A A A Nil Nil Neg Not done
69 42 M HS 3 days P A A A A A A A A Genital Nil MNG  Not done
70 32 M HS 4 days R P A P A A A A A Nil Nil Neg Not done
71 40 F HS 5 days R P A P A A A A A Nil Nil Neg Not done



















































































































73 68 M HS 3 days R A A P A A A A A Nil Nil Neg Not done
74 34 M HS 3 days R P A P A A A A A Nil Nil Neg Not done
75 11 F HS 5 days R P A P A A A A A Nil Nil Neg Not done
76 36 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
77 62 M HS 3 days R A A P A A A A A Nil Nil Neg Not done
78 56 F HS 3 days R A A P A A A A A Nil Nil Neg Not done
79 67 F HS 2 days R A A P A A A A A Nil Nil MNG  Not done
80 36 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
81 23 M HS 2 days R A A P A A A A A Nil Nil MNG  Not done
82 65 M HS 3 days R A A P A A A A A Nil Nil Neg Not done
83 37 F HS 3 days R P P A A A A A A Nasal Nil MNG  Not done
84 45 M HS 3 days R P A P A A A A A Nil Nil MNG  Not done
85 24 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
86 20 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
87 22 F HS 3 days R A A P A A A A A Nil Nil MNG  Not done
88 17 M HS 3 days R P A P A A A A A Nil Nil Neg Not done
89 43 M HS 1 day R A A P A A A A A Nasal Nil MNG  Not done



















































































































91 34 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
92 39 F HS 5 days R P A P A A A A A Nil Nil Neg Not done
93 72 F HS 4 days R P A P A A A A A Nil Nil Neg Not done
94 34 M HS 3 days R A A P A A A A A Nil Nil MNG  Not done
95 62 M HS 4 days R A A P A A A A A Nil Nil Neg Not done
96 43 F HS 5 days R P A P A A A A A Nil Nil Neg Not done
97 18 M HS 3 days R A A P A A A A A Nil Nil MNG  Not done
98 28 M CP 2 days P P P A A A A A A Nil Nil MNG  Not done




100 18 F CP 2 days P P P A A A A A A Nil Nil Neg Not done
101 12 M CP 1 day P P P A A A A A A Nil Nil Neg Not done
102 32 F HZ 3 days P P P P A P A A A Nil Nil MNG  Not done
103 58 M HZ 4 days P A P P P A P A A Nil
Lt facial
nerve palsy
MNG  Not done




105 42 F HZ 4 days P A P A A A A A A Nil Nil Neg Not done
106 53 M HZ 2 days P A P A A A A A A Nil Nil Neg Not done



















































































































108 39 M HZ 1 day P A P A A A A A A Nil Nil Neg Not done
109 68 M HZ 2 days R A P A A A A A A Nil Nil MNG  Not done
110 54 M HZ 3 days P A P A A A A A A Nil Nil Neg Not done
111 63 F HZ 3 days P A P A A A A A A Nil Nil MNG  Not done
112 64 F HZ 3 days P A P A A A A A A Nil Nil Neg Not done
113 48 F HZ 3 days P P P A A A A A A Nil Nil MNG  Not done
114 52 F HZ 3 days P A P A A A A A A Nil Nil Neg Not done
115 57 F HZ 2 days P A P A A A A A A Nil Nil Neg Not done
116 72 M HZ 4 days P A P A A A A A A Nil Nil MNG  Not done
117 47 M HZ 3 days P A P A A A A A A Nil Nil MNG  Not done
118 69 F HZ 5 days R A P A A A A A A Nil Nil MNG  Not done
119 51 M HZ 3 days P A P A A A A A A Nil Nil MNG  Not done
120 69 M HZ 4 days P P P A A A A A A Nil Nil Neg Not done
121 72 M HZ 4 days P A P A A A A A A Nil Nil Neg Not done
122 49 F HZ 3 days P A P A A A A A A Nil Nil Neg Not done
123 10 F HF 3 days _ P P P A A A A A Nil Nil _ Not done
124 2 F HF 1 day _ P P A P A A A A Nil Nil _ Not done
125 8 M HF 3 days _ P P A A A A A A Nil Nil _ Not done



















































































































































1 PVu 35 F 4 yr P E P A P P A A A 3 Positive Oral Tongue 1 mo Gen SupB SupB P
2 PVu 46 M 1 yr P E A A P P A A A 2 Positive Oral Tongue 1 mo Nil SupB SupB P





4 PVu 28 F 2 yr P E P A A P A A P 3 Positive Oral Pharynx 3 mo Nil SupB SupB P
5 PVu 30 F 2 yr P E A A P P A A A 2 Positive Skin Buc mucosa 1 yr Nil SupB IeB P ICF+




7 PVu 27 F 1 yr P V A A A P A A P 2 Positive Both Buc mucosa _ Nil SupB SupB P
8 PVu 75 F 2 yr P E P A A P P A A 3 Positive Oral Lips 10 days Nil SupB SupB P









11 PVu 56 F 3 yr P E P A A P P A A 3 Positive Oral Palate 6 mo Nil SupB SupB P
12 PVu 68 F 7 yr P E P A A P A P A 3 Positive Oral Buc mucosa 1 mo Nil SupB SupB P
13 PVu 62 F 3 yr P E P A A A A A A 1 Positive Oral Lips 3 mo Nil SupB SupB P

















































































































































15 PVu 54 M 1½ yr P E P A P P P A A 4 Positive Both Lips _ Nil SupB SupB P
16 PVu 50 F 10 yr P E P A A P A A A 2 Positive Skin Buc mucosa 10 days Nil SupB SupB P
17 PVu 28 F 1½ yr P E P P A P P A A 4 Positive Oral Lips 6 mo Nil SupB SupB P
18 PVu 40 F 3 yr P E P A A A P P P 4 Positive Oral Lips 1 mo Nil SupB SupB P
19 PVu 35 F 8 mo P E P A P P P P A 5 Negative Oral Tongue 1 mo Nil SupB SupB P
20 PVu 43 M 1½ mo P E A A A P P A A 2 Positive Both Buc mucosa _ Nil SupB SupB P
21 PVu 45 M 6 mo P E P A A P P A A 3 Positive Oral Buc mucosa 2 mo Nil SupB SupB P
22 PVu 40 F 2 mo P V P A A P P P A 4 Negative Both Buc mucosa _ Nil SupB SupB P
23 PVu 30 F 3 mo P E P P A P A A A 3 Negative Both Buc mucosa _ Nil SupB SupB P
24 PVu 62 M 2½ yr P E P A A P P A A 3 Positive Oral Buc mucosa 10 days Nil SupB SupB P
25 PVu 60 F 6 yr P E P P P P A A A 4 Positive Both Tongue _ Nil SupB SupB P
26 PVu 37 F 3 yr P E P A P P A A A 3 Positive Oral Tongue 10 days Nil SupB SupB P
27 PVu 55 F 6½ mo P E P A P P A A A 3 Positive Oral Buc mucosa 10 days Nil SupB IeB P ICF+
28 PVu 55 F 10 mo P E P A P P P A A 4 Positive Oral Tongue 1 wk Nil SupB SupB P
29 PVu 32 M 1½ yr P E P A A A A A P 2 Positive Skin Lips 6 mo
Nas,
Gen
SupB SupB P ICF+

















































































































































31 PVu 40 F 3 yr P E A A P P P A A 3 Positive Both Tongue _ Gen SupB SupB P
32 PVu 62 F 1 yr P E P A A P A P A 3 Positive Oral Buc mucosa 1 wk Nil SupB SupB P
33 PVu 27 M 2 yr P E P A P P P A A 4 Positive Oral Tongue 2 mo Nas SupB SupB P
34 PVu 42 M 1 yr P V A A P P A A A 2 Positive Skin Buc mucosa 1½ mo Gen SupB SupB P




36 PVu 42 M 6 mo P E P A A P P A P 3 Positive Oral Buc mucosa 1 wk Nil SupB SupB P
37 PVu 60 F 4 yr P E P A A A P A A 2 Positive Oral Lips 20 days Gen SupB SupB P
38 PVu 35 F 6 mo P E P A P P P A A 4 Positive Skin Buc mucosa 10 days Nil SupB SupB P




40 PVu 21 F 8 mo P E A A A P P P P 4 Positive Skin Buc mucosa 2 mo
Nas,
Gen
SupB SupB P ICF+
41 PVu 50 F 1 yr P E P A A P A A P 3 Positive Both Pharynx _ Gen SupB SupB P
42 PVu 54 F 1½ yr P E P A P P A A P 4 Positive Skin Buc mucosa 1 yr Nil SupB SupB P
43 PVu 31 F 6 yr P E P A A P A A A 2 Positive Oral Lips 1 wk Nil SupB SupB P
44 PVu 50 F 8 yr P E P A A P A A A 2 Positive Both Lips _ Nil SupB SupB P
45 PVu 35 F 9 mo P E A A A P A A A 1 Positive Skin Buc mucosa 1 mo Nil SupB SupB P

















































































































































47 PVu 55 F 6 mo P E P A A A P A A 2 Positive Oral Buc mucosa 1 mo Nil SupB SupB P
48 PVu 34 F 7 yr P E P A A A A A A 1 Positive Oral Buc mucosa 2 wk Gen SupB SupB P
49 PVu 50 F 2 wk P E P A A A A A A 1 Negative Oral Lips 1 wk Nil SupB SupB P
50 PVu 42 M 3½ yr P E A A A P A A A 1 Positive Oral Tongue 2 wk Nil SupB SupB P
51 PVu 24 M 2 yr P E P A P A P A A 2 Positive Oral Lips 1 mo Gen SupB SupB P
52 PVu 58 F 9 mo P E A A A P P A A 2 Positive Oral Lips 1 mo Nil SupB SupB P
53 PVu 35 F 5 yr P E A A A P A A A 1 Positive Oral Lips 3 wk Nil SupB SupB P
54 PVu 70 F 8 mo A E P A P P P A A 4 Positive _ Palate _ Nil _ SupB P ICF+
55 PVu 60 F 1 yr A E P A A P A A A 2 Positive _ Lips _ Nil _ SupB P ICF+
56 PVu 44 F 1 yr A E P A A A A A A 1 Positive _ Lips _ Nil _ SupB P ICF+
57 PVu 33 F 4 mo A E P A P A A A A 2 Negative _ Tongue _ Nil _ SupB P ICF+
58 PVu 45 F 3 yr A E P A A P A A A 2 Positive _ Lips _ Nil _ SupB P ICF+
59 PVu 36 F 5 yr A E A A A P P A A 2 Positive _ Buc mucosa _ Nil _ SupB P ICF+
60 PVu 65 M 8 mo A E P A P P P A P 5 Positive _ Tongue _ Nil _ SupB P ICF+
61 PVu 17 F 3 mo A V P A A P P A A 3 Positive _ Buc mucosa _ Nil _ SupB P ICF+

















































































































































63 PVu 31 F 11 mo P A A A A A A A A _ _ _ _ _ Nil SupB _ A _
64 PVu 35 F 2 mo P A A A A A A A A _ _ _ _ _ Nil SupB _ A _
65 PVu 41 M 1 yr P A A A A A A A A _ _ _ _ _ Nil SupB _ A _
66 PVu 42 F 5 mo P A A A A A A A A _ _ _ _ _ Nil SupB _ A _
67 PVu 60 F 3½ mo P A A A A A A A A _ _ _ _ _ Nil SupB _ A _
68 PVu 38 F 1 yr P A A A A A A A A _ _ _ _ _ Nil SupB _ A _





70 PVg 45 F 4 wk P E P A A A A A A 1 Negative Oral Lips 3 wk Nil SupB SupB P ICF+
71 PVg 42 M 3 mo P E A A A P A A A 1 Negative Both Buc mucosa _ Nil SupB SupB P ICF+
72 PF 48 F 2 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
73 PF 38 F 1 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
74 PF 43 F 2 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
75 PF 72 M 3 wks P A A A A A A A A _ _ _ _ _ Nil ScB _ A
76 PF 54 F 2½ yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
77 PF 46 F 2 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A

















































































































































79 PF 39 F 1 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
80 PF 53 M 11 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
81 PF 31 F 3 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
82 PF 49 M 2½ yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
83 PE 42 F 2 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
84 PE 51 F 1½ yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
85 PE 52 F 15 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
86 PE 48 M 2 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
87 PE 54 F 2 yr P A A A A A A A A _ _ _ _ _ Nil ScB _ A
88 PE 42 F 8 mo P A A A A A A A A _ _ _ _ _ Nil ScB _ A
89 BP 37 F 6 wk P E A P A P A A A 2 Negative Skin Gingiva 2 mo Nil SeB SeB A
90 BP 60 M 11 mo P B/E A P A P A P A 3 Negative Skin Gingiva 3 mo Nil SeB SeB A
91 BP 72 F 2½ yr P B/E A A A P A A A 1 Negative Oral Buc mucosa 6 mo Nil SeB SeB A
92 BP 24 M 3 yr P B A A A P A A A 1 Negative Skin Buc mucosa 1 mo Nil SeB SeB A
93 BP 54 F 2 yr P E A A A P A A A 1 Negative Skin Buc mucosa 1 mo Nil SeB SeB A
94 BP 50 F 6 mo P E A P A A A A A 1 Negative Oral Gingiva 2 mo Nil SeB SeB A
95 BP 47 F 3 yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
96 BP 65 M 10 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
97 BP 60 F 2 yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A

















































































































































99 BP 65 F 9 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
100 BP 60 M 2½ yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
101 BP 85 F 7 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
102 BP 45 M 2 yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
103 BP 63 M 1 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
104 BP 53 M 6 yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
105 BP 63 F 1 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
106 BP 60 F 2½ yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
107 BP 65 M 3 yr P A A A A A A A A _ _ _ _ _ Nil SeB _ A
108 BP 61 F 5 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
109 BP 32 F 4 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A
110 BP 65 M 15 mo P A A A A A A A A _ _ _ _ _ Nil SeB _ A








113 DH 65 M 3 mo P A A A A A A A A _ Negative _ _ _ Nil SeB _ A












































































































































1 23 F 2 wk EM Ifosfamide/Etoposide P 27% + + _ _ _ _ _ Oral 2 days _ _
Hodgkin's
lymphoma
2 16 M 2 yrs EM Amoxicillin P 36% + + + _ _ + + Oral 3 days _ _ _
3 60 M 1 mo EM Phenytoin P 72% + + + _ _ + _ Oral 2 days _ _ _
4 28 M 3 yrs EM Cephalexin P 54% + + _ _ _ _ _ Both _ _ _ _
5 58 M 5 days SJS Cefotaxime P 9% + + _ + _ _ _ Oral 3 days _ _ Diabetesmellitus
6 17 M 15 days SJS Diclofenac P 18% + + _ _ _ _ _ Oral 1 day _ _ _
7 18 F 10 days SJS Cotrimoxazole P 9% + + _ _ _ _ _ Skin 1 day _ _ _
8 32 M 2 days TEN NSAIDS P 100% + + _ + _ + _ Oral 1 day Genital HIV +ve _
9 30 F 1 week TEN Diclofenac P 81% + + _ _ _ _ _ Skin 1 day Conjunctival _ _
10 34 F 2 days TEN Carbamazepine P 45% + + _ _ _ _ _ Oral 1 day _ _ GTCS
11 23 F 5 days TEN Carbamazepine P 46% + + _ _ _ _ _ Oral 3 days Genital _ _
12 40 M 1 day FDE Paracetamol P _ _ _ _ _ _ _ _ _ _ _ _ _
KEY TO MASTER CHART
A. VIRAL INFECTIONS:
HS – Herpes simplex, CP – Varicella, HZ – Herpes zoster, HF –
Hand, foot & mouth disease
P – Primary episode, R – Recurrent episode
P –  Present, A – Absent
MNG – Multinucleated giant cells, Neg – Negative
B. AUTOIMMUNE BULLOUS DISEASES:
PVu – Pemphigus vulgaris, PVg – Pemphigus vegetans
PF – Pemphigus foliaceous, PE – Pemphigus erythematosus
BP – Bullous pemphigoid, DH – Dermatitis herpetiformis
Oral Morphology: B – Bulla, E – Erosion, V – Vesicle, A- Absent
Duration: wk – week, mo – month, yr – year
Other mucosa: Nas – Nasal mucosa, Gen – Genital mucosa,
                        Conj – Conjunctiva
Biopsy: SupB – Suprabasal bulla, IeB – Intraepidermal bulla,
ScB  –  Subcorneal bulla, SeB – Subepidermal bulla
Tzanck: P – Acantholytic cells present, A – Negative
C. DRUG INDUCED:
BSA – Body Surface Area
EM – Erythema multiforme
SJS – Stevens Johnson syndrome





         a. Name:                                               d. occupation    & income:
         b. Age/sex:                                           e. Address:
         c. OP/IP No:
3.  Complaints:
4.  H/o presenting illness:
          a. Onset:
          b. Duration:
          c. Symptoms:
          e. Oral lesions preceded/ followed skin lesions
          f. H/o drug intake prior to the onset of lesions
g. H/o remissions & exacerbations (Rx, sunlight, foods, etc.,)
          h. H/o photosensitivity
          i. H/o loss of weight & appetite
          j. H/o dysphagia, odynophagia
          k. H/o abdominal pain, diarrhoea
          l. H/o sharp teeth & ill fitting dentures.
5. Past history:
- similar illness:
- DM, HT, TB
6.  Family history:
      - similar illness:
7.  Personal history:
   - diet
      - smoking/ alcohol consumption/ pan chewing
8.  Menstrual history:
9.  General examination:
     Pallor/ jaundice/cyanosis/clubbing/pedal edema/lymphadenopathy
10.  Vital signs:
           PR:
          BP:
11. Systemic examination:
                  CVS:
RS:
       ABDOMEN:
CNS:
12. Dermatological examination:
         a)  Skin:
         b)  Oral cavity:
                Vesicle/ bulla/ erosion: Initial site of involvement:
                No: Bleeding:
                Site(s):                                          Scarring:
                Shape: Hyperpigmentation:
                Borders:                                        Nikolsky’s sign:
         c)  Genital examination:
         d)  Other mucosa: Conjunctiva, nasal, oropharyngeal
         e)  Hair:
         f) Nail:
INVESTIGATIONS:
i. Blood:









x. Tzanck smear from oral mucosa:
xi. Tongue scraping for candida:
xii. Skin biopsy:
xiii. Mucosal Biopsy:
xiv. Direct immunofluorescence (if done):
xv. HSV  IgM ELISA (if done):
xvi. Viral culture (if done):

